FILE:LH/LH-8K-20101203160119.txt.gz
EVENTS:	Completion of Acquisition or Disposition of Assets	Financial Statements and Exhibits
TEXT:
ITEM: Completion of Acquisition or Disposition of Assets
ITEM: Financial Statements and Exhibits
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Pursuant to the terms of an Asset Purchase Agreement (the Agreement), dated September 13, 2010, between Laboratory Corporation of America Holdings (the Company) and Genzyme Corporation (Genzyme), on November 30, 2010 the Company completed the acquisition of Genzyme Genetics, a business unit of Genzyme (the Acquisition).  As a result of the Acquisition, the Company acquired from Genzyme substantially all of the assets of Genzyme Genetics and assumed substantially all of the liabilities of Genzyme Genetics.  Pursuant to the Agreement, the tota l consideration paid by the Company for Genzyme Genetics was $925 million in cash, subject to a limited post-closing purchase price adjustment relating to acquired working capital.
 
In connection with the Acquisition the Company issued $925 million in debt securities in a public offering pursuant to an effective shelf registration statement on Form S-3, the net proceeds of which were used to fund a portion of the purchase price of the Acquisition, and for general corporate purposes.
 
Genzyme Genetics is a leading provider of complex reproductive and oncology testing services, including genetic counseling.
 
 
 
 
(a)  Financial Statements of Business Acquired
 
(b)  Pro Forma Financial Information
 
 
(d)  Exhibits
 
 
 
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
December 3, 2010
 
 
 
 
 
EXHIBIT INDEX
 


